For the first time in four decades, pancreatic cancer patients have reason to hope as two experimental drugs show meaningful survival gains in clinical trials, offering months of life where progress had long stalled.
The breakthrough comes as pancreatic cancer, often diagnosed late and notoriously resistant to treatment, threatens to become the second deadliest cancer in developed nations after lung cancer. In mid-April, Revolution Medicines reported that its drug daraxonrasib doubled survival in a Phase 3 trial, with half of the 460 patients living beyond 13 months compared to under seven months on standard chemotherapy. No deaths were attributed to the drug, and side effects like diarrhea and fatigue were deemed manageable by the company.
Separately, Actuate Therapeutics’ elraglusib, tested in a 233-patient trial across North America and Europe, showed 44% of patients alive after one year versus 22% on chemotherapy alone, reducing the risk of death by 38%. At two years, 13% of those on elraglusib remained alive, while none in the chemotherapy-only group reached that milestone. The drug works by inhibiting GSK-3 beta, a protein that helps cancer cells survive and evade the immune system.
These results arrive against a backdrop of stagnation. As recently as 2024, no significant advances had emerged since the 1980s, leaving patients with few options beyond aggressive chemotherapy regimens that rarely extend life beyond a year. Now, researchers like Patrick Mehlen of the Léon Bérard Cancer Center in Lyon point to a second approach: a molecule designed to block cancer cells from developing resistance to chemotherapy, which in early trials added an average of six months to survival — a meaningful gain in a disease where even small improvements are rare.
While both drugs require further validation — Mehlen’s resistance-blocking study remains preliminary and awaits a larger trial slated for late 2026, and Actuate’s findings need Phase 3 confirmation — the convergence of results signals a potential turning point. Experts caution that neither drug is a cure, but for a cancer with a five-year survival rate below 13%, any extension of life represents a profound shift.
Revolution Medicines plans to seek regulatory approval for daraxonrasib after presenting full trial results at a Chicago congress in late May, citing what it calls “definitive” survival benefits. Meanwhile, the looming epidemiological threat persists: projections indicate pancreatic cancer could claim 16,000 new lives annually in France by 2030, underscoring the urgency of translating these advances into widespread access.
How the two drugs work differently to extend survival
Daraxonrasib targets mutated KRAS, a genetic driver found in most pancreatic cancers, directly inhibiting the cancer’s growth signal. Elraglusib, by contrast, disables GSK-3 beta, a protein that helps tumor cells resist treatment and hide from immune detection. While both aim to overcome chemotherapy resistance, they attack distinct biological mechanisms — one upstream in cancer signaling, the other in cellular survival pathways.
Why experts urge caution despite the optimism
Researchers stress that daraxonrasib’s Phase 3 data, while promising, await full publication and independent review, and elraglusib’s one-year survival benefit must be replicated in larger Phase 3 trials before regulatory consideration. History tempers enthusiasm: past breakthroughs in pancreatic cancer have often failed to translate from early signs to lasting patient benefit, underscoring the need for rigorous validation before declaring a new standard of care.
What makes pancreatic cancer so hard to treat?
Pancreatic cancer is often diagnosed at an advanced stage because symptoms like jaundice or weight loss appear late, and the tumor’s dense stroma creates a barrier that blocks drug delivery and shields cancer cells from both chemotherapy and immune attack.
Could these drugs work for other cancers?
Actuate Therapeutics notes that elraglusib’s mechanism — inhibiting GSK-3 beta — shows potential in preclinical models of other solid tumors, though no clinical data beyond pancreatic cancer has been released yet; Revolution Medicines’ daraxonrasib is specifically designed for KRAS-mutated cancers, which include subsets of lung and colorectal cancer, but its efficacy in those contexts remains under investigation.
